Guangdong True Health Valuation Multiples

Guangdong True Health is valued at $211M as of November 2026, a 77.6x revenue multiple. In the last fiscal year, Guangdong True Health revenue was $2M and Guangdong True Health EBITDA was ($11M).

Guangdong True Health Overview

About Guangdong True Health

Guangdong True Health Medical Technology Development Co Ltd is principally engaged in the research and development, manufacture and sale of surgical robots and disposables. It is focused on commercializing percutaneous puncture and ablation surgical robots in China. The company's core Product is a percutaneous puncture surgical robot available in four models, namely, TH-S1, TH-S, TH-S Pro and TH-SA. Its pipeline also includes two key products, the percutaneous microwave ablation surgical robot TH-X MW for the treatment of liver and lung tumors and the percutaneous microwave ablation surgical robot TH-X HMW for the treatment of liver tumors. The company derived the majority of its revenue from product sales to distributors.


Founded

2018

HQ

China

Employees

156

Financials (Last FY)

Revenue: $2M
EBITDA: ($11M)

EV

$142M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Guangdong True Health Financials

Guangdong True Health reported last fiscal year revenue of $2M and negative EBITDA of ($11M).

In the same fiscal year, Guangdong True Health generated $1M in gross profit, ($11M) in EBITDA losses, and had net loss of ($14M).


Guangdong True Health P&L

In the most recent fiscal year, Guangdong True Health reported revenue of $2M and EBITDA of ($11M).

Guangdong True Health is unprofitable as of last fiscal year, with gross margin of 76%, EBITDA margin of (629%), and net margin of (740%).

See analyst estimates for Guangdong True Health
Last FY2025202620272028
Revenue$2M$2M
Gross Profit$1M$1M
Gross Margin76%76%
EBITDA($11M)($11M)
EBITDA Margin(629%)(629%)
EBIT Margin(750%)(750%)
Net Profit($14M)($14M)
Net Margin(740%)(740%)
Net Debt($26M)-

Financial data powered by Morningstar, Inc.

Guangdong True Health Stock Performance

Guangdong True Health has current market cap of $211M, and enterprise value of $142M.

Market Cap Evolution


Guangdong True Health's stock price is $5.93.

Guangdong True Health has an EPS (earnings per share) of $-0.38.

See more trading valuation data for Guangdong True Health
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$142M$211M0.0%---$-0.38

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Guangdong True Health Valuation Multiples

Guangdong True Health trades at 77.6x EV/Revenue multiple, and (12.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for Guangdong True Health

Guangdong True Health Financial Valuation Multiples

As of November 8, 2026, Guangdong True Health has market cap of $211M and EV of $142M.

Guangdong True Health has a P/E ratio of (15.6x).

Last FY2025202620272028
EV/Revenue77.6x77.6x
EV/EBITDA(12.3x)(12.3x)
EV/EBIT(10.3x)(10.3x)
EV/Gross Profit101.6x101.6x
P/E(15.6x)(15.6x)
EV/FCF(9.9x)(9.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Guangdong True Health Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Guangdong True Health Margins & Growth Rates

In the most recent fiscal year, Guangdong True Health reported gross margin of 76%, EBITDA margin of (629%), and net margin of (740%).

See estimated margins and future growth rates for Guangdong True Health

Guangdong True Health Margins

Last FY2025202720282029
Gross Margin76%76%
EBITDA Margin(629%)(629%)
EBIT Margin(750%)(750%)
Net Margin(740%)(740%)
FCF Margin(782%)(782%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Guangdong True Health Operational KPIs

Guangdong True Health's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.1M for the same period.

Access forward-looking KPIs for Guangdong True Health
Last FY2025202620272028
Revenue per Employee$0.0M-
Opex per Employee$0.1M-
S&M Expenses to Revenue133%133%
G&A Expenses to Revenue211%211%
R&D Expenses to Revenue467%467%
Opex to Revenue826%826%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Guangdong True Health Competitors

Guangdong True Health competitors include Utah Medical, Pro-Dex, Ascom, TriSalus Life Sciences, SmartVest, Anika Therapeutics, Volatus Aerospace, Median Technologies, AOTI and RxSight.

Most Guangdong True Health public comparables operate across Medical Devices, Autonomous AI & Robotics, BioTech, DeepTech and Generative AI.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Utah Medical$39M$17M3.1x-7.0x-
Pro-Dex$78M$20M2.7x2.6x10.4x13.7x
Ascom$358M$39M0.5x0.5x4.9x4.3x
TriSalus Life Sciences$45M($34M)4.2x3.6x(5.6x)(10.5x)
SmartVest$74M$15M2.8x2.7x13.7x11.3x
Anika Therapeutics$113M($5M)1.6x1.5x(33.1x)9.8x
Volatus Aerospace$24M($8M)8.3x7.4x(25.0x)(23.9x)
Median Technologies$26M($28M)5.8x5.5x(5.4x)(7.5x)

This data is available for Pro users. Sign up to see all Guangdong True Health competitors and their valuation data.

Start Free Trial

Guangdong True Health VC Funding History

Before going public, Guangdong True Health raised $14M in total equity funding, across 1 round.


Guangdong True Health Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Nov-23Series B-$14M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Guangdong True Health

When was Guangdong True Health founded?Guangdong True Health was founded in 2018.
Where is Guangdong True Health headquartered?Guangdong True Health is headquartered in China.
How many employees does Guangdong True Health have?As of today, Guangdong True Health has over 156 employees.
Is Guangdong True Health publicly listed?Yes, Guangdong True Health is a public company listed on HKEX.
What is the stock symbol of Guangdong True Health?Guangdong True Health trades under 02697 ticker.
When did Guangdong True Health go public?Guangdong True Health went public in 2026.
Who are competitors of Guangdong True Health?Guangdong True Health main competitors include Utah Medical, Pro-Dex, Ascom, TriSalus Life Sciences, SmartVest, Anika Therapeutics, Volatus Aerospace, Median Technologies, AOTI, RxSight.
What is the current market cap of Guangdong True Health?Guangdong True Health's current market cap is $211M.
What is the current revenue of Guangdong True Health?Guangdong True Health's last fiscal year revenue is $2M.
What is the current EV/Revenue multiple of Guangdong True Health?Current revenue multiple of Guangdong True Health is 77.6x.
Is Guangdong True Health profitable?No, Guangdong True Health is not profitable.
How many companies Guangdong True Health has acquired to date?Guangdong True Health hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Guangdong True Health has invested to date?Guangdong True Health hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Guangdong True Health

Lists including Guangdong True Health

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial